Performance characteristics of HIV-2 serology reagents on blood from SIV/HIV-2 infected monkeys.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Performance characteristics of HIV-2 serology reagents on blood from SIV/HIV-2 infected monkeys.

Symp Nonhum Primate Models AIDS. 1993 Sep 19-22;11:abstract no. 52. Unique Identifier : AIDSLINE PRIM11/94191647
Yee JL; Jennings MB; Lowenstine LJ; Lerche NW; Dept. of Medical Pathology, University of California, Davis.

Abstract: Over the past five years, we have tested more than 20,000 sera from humans and non-human primates for antibodies to SIV/HIV-2, using first generation reagents prepared from HIV-2 viral lysate. The increasing demands for testing, and the wider commercial availability of new generation reagents have led us to evaluate the performance characteristics of various HIV-2 reagents for SIV/HIV-2 antibody detection. We evaluated assays using viral lysate (ROD, NIH-Z, GB-122), recombinant protein (env and gag) and synthetic peptide (env and gag) antigens as targets. The methods included enzyme immunoassays, Western blots, and rapid/simple tests. We also evaluated recently released combination HIV-1, 2 tests. These assays were evaluated with sera from rhesus macaques, stumptailed macaques, sooty mangabey monkeys, and African green monkeys infected naturally or experimentally with HIV-2, SIVmac, SIVsmm, SIVstm, SIVagm. All the HIV-2 reagents (viral lysate, recombinant protein, synthetic peptide) detected antibodies to all the strains of SIV tested. By Western blot, env cross-reactivity was more broadly detected than gag. Using sequential sera from animals undergoing seroconversion we hope to determine which reagents will detect antibody earliest in infection. HIV-2 reagents provide a sensitive, standardized means of detecting SIV/HIV-2 antibodies in humans and non-human primates. They are valid tools in field studies for seroprevalence/new isolates, colony screening and management, following the course of infection/disease in experimentally infected monkeys, and monitoring human exposure to infected monkeys.

Keywords: Acquired Immunodeficiency Syndrome/*BLOOD/IMMUNOLOGY/TRANSMISSION Animal Antibodies, Viral/ANALYSIS/*BLOOD Cercocebus Cercopithecus aethiops Comparative Study Human HIV Antibodies/ANALYSIS/*BLOOD HIV-2/*IMMUNOLOGY Macaca Macaca mulatta Simian Acquired Immunodeficiency Syndrome/*BLOOD/IMMUNOLOGY/ TRANSMISSION SIV/*IMMUNOLOGY ABSTRACT
940730
M9470871

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .